Allan Reine
CIK 1714023 · Chief Executive Officer · last filed 2026-02-27
Allan Reine is a Chief Executive Officer who has filed 18 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing, for PRME, was dated Feb 27, 2026. Across all open-market trades the lifetime net is +$460.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $647.2K across reported positions. 5 SEC filings were submitted jointly with PALVELLA THERAPEUTICS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PIRS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
255 STATE STREET
BOSTON, MA 02109
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRME | Chief Executive Officer | 125,000 | $4.30 | $537.5K | $147.2K | 9 | 2026-02-27 |
| FHTX | Chief Financial Officer | 53,784 | $2.04 | $109.7K | $0 | 5 | 2024-01-17 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Chief Financial Officer | 562 | $13.60 | $7.6K | $313.4K | 4 | 2019-02-28 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-27 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-08-05 | PRME | Mixed | — | $0 | EDGAR |
| 2025-05-22 | PRME | Buy (P) | +125,000 | $147.2K | EDGAR |
| 2025-05-19 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-05-12 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-03-03 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-12-09 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-05-21 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-01-19 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-01-17 | FHTX | — | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.